Peniket A J, Ruiz de Elvira M C, Taghipour G, Cordonnier C, Gluckman E, de Witte T, Santini G, Blaise D, Greinix H, Ferrant A, Cornelissen J, Schmitz N, Goldstone A H
Nuffield Department of Clinical Laboratory Sciences, John Radcliffe Hospital, Oxford, UK.
Bone Marrow Transplant. 2003 Apr;31(8):667-78. doi: 10.1038/sj.bmt.1703891.
The role of allogeneic bone marrow transplantation in lymphoma remains uncertain. We have analyzed 1185 allogeneic transplants for lymphoma reported to the EBMT registry between 1982 and 1998 and compared the results with those of 14687 autologous procedures performed over the same period. Patients receiving allogeneic transplants were subdivided according to histology: low-grade non-Hodgkin's lymphoma (NHL) 231 patients; intermediate-grade NHL 147 patients; high-grade NHL 255 patients; lymphoblastic NHL 314 patients; Burkitt's lymphoma 71 patients; and Hodgkin's disease 167 patients. These patients received allogeneic transplants as their first transplant procedure. Actuarial overall survival (OS) at 4 years from transplantation was: low-grade NHL 51.1%; intermediate-grade NHL 38.3%; high-grade NHL 41.2%; lymphoblastic lymphoma 42.0% years; Burkitt's lymphoma 37.1%; and Hodgkin's disease 24.7% years. These outcomes are relatively poor because of the high procedure-related mortality associated with these procedures, particularly in patients with Hodgkin's disease (51.7% actuarial procedure-related mortality at 4 years). Multivariate analysis showed that for all lymphomas apart from Hodgkin's disease, status at transplantation significantly affected outcome. A matched analysis was performed: for all categories of lymphoma, OS was better for autologous than for allogeneic transplantation. Relapse rate was better in the allogeneic group for low-, intermediate- and high-grade, and lymphoblastic NHL. It was equivalent for Burkitt's lymphoma and worse in the allogeneic group for Hodgkin's disease. Allogeneic transplantation appears to be superior to autologous procedures in terms of producing a lower relapse rate. The toxicity of allogeneic procedures must however be reduced before this translates into an improvement in OS.
异基因骨髓移植在淋巴瘤治疗中的作用仍不明确。我们分析了1982年至1998年间向欧洲血液与骨髓移植登记处(EBMT)报告的1185例淋巴瘤异基因移植病例,并将结果与同期进行的14687例自体移植手术的结果进行了比较。接受异基因移植的患者根据组织学进行了细分:低度非霍奇金淋巴瘤(NHL)231例;中度NHL 147例;高度NHL 255例;淋巴母细胞性NHL 314例;伯基特淋巴瘤71例;霍奇金病167例。这些患者接受异基因移植作为他们的首次移植手术。移植后4年的精算总生存率(OS)为:低度NHL 51.1%;中度NHL 38.3%;高度NHL 41.2%;淋巴母细胞性淋巴瘤42.0%;伯基特淋巴瘤37.1%;霍奇金病24.7%。由于这些手术相关的高死亡率,这些结果相对较差,尤其是在霍奇金病患者中(4年精算手术相关死亡率为51.7%)。多因素分析表明,除霍奇金病外,所有淋巴瘤患者移植时的状态均显著影响预后。进行了匹配分析:对于所有类型的淋巴瘤,自体移植的OS均优于异基因移植。异基因组在低度、中度和高度以及淋巴母细胞性NHL中的复发率较好。伯基特淋巴瘤的复发率相当,而异基因组在霍奇金病中的复发率更差。在降低复发率方面,异基因移植似乎优于自体移植手术。然而,在异基因移植转化为OS改善之前,必须降低其毒性。